ContraFect Corporation (CFRXQ)

OTCMKTS · Delayed Price · Currency is USD
0.0002
0.00 (0.00%)
At close: Apr 17, 2025
-99.05%
Market Cap 2.14K
Revenue (ttm) n/a
Net Income (ttm) -24.14M
Shares Out 10.70M
EPS (ttm) -5.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,502
Average Volume 2,330
Open 0.0002
Previous Close 0.0002
Day's Range 0.0002 - 0.0002
52-Week Range 0.0001 - 0.0300
Beta -14.31
RSI 48.34
Earnings Date n/a

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator as... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 23
Stock Exchange OTCMKTS
Ticker Symbol CFRXQ
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.